308 related articles for article (PubMed ID: 35328625)
21. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
22. Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.
Zhou L; Zhang C; Yang X; Liu L; Hu J; Hou Y; Tao H; Sugimura H; Chen Z; Wang L; Chen K
Clin Transl Med; 2021 Jun; 11(6):e449. PubMed ID: 34185414
[TBL] [Abstract][Full Text] [Related]
23. Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.
Masre SF; Jufri NF; Ibrahim FW; Abdul Raub SH
Rev Med Virol; 2021 Sep; 31(5):1-9. PubMed ID: 33368788
[TBL] [Abstract][Full Text] [Related]
24. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
Sekhar KR; Wang J; Freeman ML; Kirschner AN
PLoS One; 2019; 14(4):e0214670. PubMed ID: 30933998
[TBL] [Abstract][Full Text] [Related]
25. Identification of key factors shaping integrated levels of ACE2 and TMPRSS2 expression in head and neck squamous cell carcinoma.
Zheng T; Yue P; Han T; Zhang K; Jiang Y; Wang S; Jiang L; Zhao B; Zhang X; Yan X
Front Biosci (Landmark Ed); 2021 Oct; 26(10):740-751. PubMed ID: 34719202
[No Abstract] [Full Text] [Related]
26. SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
Pang X; Zhang J; He X; Gu Y; Qian BZ; Xie R; Yu W; Zhang X; Li T; Shi X; Zhou Y; Cui Y
Oxid Med Cell Longev; 2021; 2021():5806602. PubMed ID: 34721759
[TBL] [Abstract][Full Text] [Related]
27. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
[TBL] [Abstract][Full Text] [Related]
28. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
29. Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.
Peter MR; Bilenky M; Davies A; Isserlin R; Bader GD; Fleshner NE; Hirst M; Zoubeidi A; Bapat B
Sci Rep; 2021 Mar; 11(1):6630. PubMed ID: 33758253
[TBL] [Abstract][Full Text] [Related]
30. Gene expression analysis identifies genes associated with SARS-COV-2 receptors, ACE2 and TMPRSS2, in normal human lung tissues.
Hu RW; Liu C; Gong JP; Cao ZX
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2409-2414. PubMed ID: 33755980
[TBL] [Abstract][Full Text] [Related]
31. Host cell entry mediators implicated in the cellular tropism of SARS‑CoV‑2, the pathophysiology of COVID‑19 and the identification of microRNAs that can modulate the expression of these mediators (Review).
Katopodis P; Randeva HS; Spandidos DA; Saravi S; Kyrou I; Karteris E
Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34935057
[TBL] [Abstract][Full Text] [Related]
32. AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation.
Hettel D; Zhang A; Alyamani M; Berk M; Sharifi N
Endocrinology; 2018 Aug; 159(8):2884-2890. PubMed ID: 29850791
[TBL] [Abstract][Full Text] [Related]
33. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract][Full Text] [Related]
34. Single-cell RNA sequencing analysis of SARS-CoV-2 entry receptors in human organoids.
Mahalingam R; Dharmalingam P; Santhanam A; Kotla S; Davuluri G; Karmouty-Quintana H; Ashrith G; Thandavarayan RA
J Cell Physiol; 2021 Apr; 236(4):2950-2958. PubMed ID: 32944935
[TBL] [Abstract][Full Text] [Related]
35. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
[TBL] [Abstract][Full Text] [Related]
37. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
Cao B; Qi Y; Zhang G; Xu D; Zhan Y; Alvarez X; Guo Z; Fu X; Plymate SR; Sartor O; Zhang H; Dong Y
Oncotarget; 2014 Mar; 5(6):1646-56. PubMed ID: 24722067
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of ACE2 expression by SARS-CoV-2 worsens the prognosis of KIRC and KIRP patients via metabolism and immunoregulation.
Tang Q; Wang Y; Ou L; Li J; Zheng K; Zhan H; Gu J; Zhou G; Xie S; Zhang J; Huang W; Wang S; Wang X
Int J Biol Sci; 2021; 17(8):1925-1939. PubMed ID: 34131396
[No Abstract] [Full Text] [Related]
39. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression.
Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C
Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067
[TBL] [Abstract][Full Text] [Related]
40. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
